<DOC>
	<DOCNO>NCT03097107</DOCNO>
	<brief_summary>To evaluate safety efficacy Saroglitazar Magnesium 1 , 2 , 4 mg patient fast triglyceride ≥500 mg/dL ≤1500 mg/dL .</brief_summary>
	<brief_title>Evaluate Safety Efficacy Saroglitazar Magnesium Patients With Fasting Triglyceride ≥500 mg/dL ≤1500 mg/dL</brief_title>
	<detailed_description>SARO.15.001.04 multicenter , prospective , randomize , double-blind , placebo-controlled , parallel arm , 12-week study design evaluate safety efficacy Saroglitazar Magnesium 1 , 2 4 mg patient fast triglyceride ≥500 mg/dL ≤1500 mg/dL . A total 124 subject enrol ratio 1:1:1:1 receive either Saroglitazar Magnesium 1 mg , Saroglitazar Magnesium 2 mg , Saroglitazar Magnesium 4 mg , placebo .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>1 . Adults subject ( ≥18 year ) either gender . 2 . Average fasting TGC ≥500 mg/dL ≤1500 mg/dL ( Visits 2 2.1 ) . 3 . Able willing give write informed consent comply requirement study protocol . 1 . History pancreatitis within 6 month initial screen visit ( V1 ) ; patient episode pancreatitis V1 , randomization randomize . 2 . History &gt; 5 % weight gain weight loss participation weight gain/loss program past 6 month maintenance phase Visit 1 ( V1 ) . 3 . Diabetic ( per ADA guideline ) subject HbA1c ≥9.5 % . 4 . Subjects insulin , GLP1 agonists , DPP4 inhibitor , SGLT 2 inhibitor , pramlintide , thiazolidinediones ( TZDs ) glitazars 3 month prior Visit 1 ( V1 ) . 5 . Subjects antiobesity medication within 6 month screen . ( i.e . orlistat , lorcaserin , phentermine , naltrexone etc. ) . 6 . Subjects drug may promote weight loss ( i.e . antiepileptic agent topiramate , zonisamide antidepressant bupropion ) may take , unless dose stable 3 month indication use weight loss . 7 . Subjects nutraceutical supplement within 3 month Visit 1 ( Refer Annexure 1 ) . 8 . Subjects unexplained hematuria prior first noted screening . 9 . Subjects anemia undergoing repletion deficiency ( iron , folate , B12 ) maintenance phase Visit 1 ( V1 ) . 10 . Subjects concomitant lipidlowering medication willing participate Leadin/Runin Phase ( Please refer Leadin/Runin Phase ) . 11 . Subjects heart failure NYHA class ( IIIIV ) , unstable angina , Acute Myocardial Infarction , Stroke , Transient ischaemic attack , coronary revascularisation procedure hospitalization acute coronary syndrome discharge within 6 month prior screen . 12 . Patients Left Ventricular dysfunction ( Left Ventricular Ejection Fraction ( LVEF ) &lt; 40 % , measure ECHO ) 13 . Uncontrolled hypertension ( SBP &gt; 160 and/or DBP &gt; 100 ) . 14 . An uncontrolled thyroid disorder Uncontrolled hyperthyroidism define history hyperthyroidism either treat either radioactive iodine ( RAI ) and/or surgery treat RAI and/or surgery , require ongoing continuous intermittent use thyroid hormone synthesis inhibitor ( i.e . methimazole proplythiouracil ) within 6 month V1 Uncontrolled hypothyroidism define initiation thyroid hormone replacement therapy dose adjustment replacement therapy within 3 month V1 . 15 . History GI malabsorption history gastric bypass , banding , diversional bariatric surgery . 16 . History active liver disease gall stone hepatic dysfunction demonstrate AST ALT ≥2 time upper normal limit ( UNL ) bilirubin ≥1.5 time UNL Screening visit ( V1 ) . 17 . History myopathy evidence active muscle disease demonstrate CPK ≥5 time UNL Screening visit . 18 . History concurrent serious illness malignancy ( except successfully treat basal squamous cell carcinoma skin ) within past 5 year ( e.g . tuberculosis , HIV ) . 19 . Positive HIV , hepatitis A , hepatitis B , hepatitis C screening . 20 . History excessive consumption alcoholic beverage ( consumes &gt; 2 alcoholic drink per day &gt; 14 alcoholic drink per week , engage binge drink ) . For remainder study , subject agree refrain excessive alcohol consumption ( i.e. , &gt; 2 alcoholic beverage per day ) , maintain current dietary regimen , alter normal activity routine . ( Note : Patient drink alcohol 24 hr prior site visit ) . 21 . History known allergy , sensitivity intolerance study drug formulation ingredient . 22 . Renal dysfunction demonstrate eGFR &lt; 50 mL/min/1.73 m2 . 23 . History clinically significant* systemic steroid therapy ( intramuscular , intravenous , intraarticular , oral route ) within 3 month screen visit ( V1 ) anticipate requirement systemic steroid therapy V1 ( however , topical , ophthalmic inhaled steroid allow ) . *Clinically significant ' ( i.e . 5 day systemic steroid treatment within 3 month V1 ) 24 . History long term continuous ( i.e . great 3 month use minimum 4 day per week ) use nonsteroidal antiinflammatory drug treatment osteoarthritis , rheumatoid arthritis etc . 25 . Participation clinical trial past 3 month . 26 . Subjects donate / receive blood within 3 month screen . 27 . Pregnancy ( include positive serum pregnancy test Visit 1 ) , lactation plan pregnancy/lactation time study followup period . 28 . Subjects hormonal contraceptive / hormone replacement therapy . 29 . Women childbearing potential ( WOCBP ) men , UNLESS use effective contraceptive method , intra uterine device mechanical contraception method condom diaphragm spermicide ) throughout study . For male patient , contraception measure ( condom spermicide ) must take study , either male participant female partner . ( Note : Enrolled female otherwise must surgically sterilize least 6 month precede Visit 1 postmenopausal , define 12 month menses without alternative medical cause ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>hypertriglyceridemia</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>saroglitazar magnesium</keyword>
	<keyword>lipid disorder</keyword>
</DOC>